- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01692873
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors (PACAomics)
Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat.
Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response.
This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13009
- Marine GILABERT, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suspicion of pancreatic adenocarcinoma
- Patient > 18 years old
- Social Security affiliation
- Signed informed consent
Exclusion Criteria:
- Patient in emergency situation
- Major person being the object of a legal protective measure or unable to express its consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: suspected pancreatic tumor
Realization of pancreatic tumor biopsy and blood samples
|
Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers
Time Frame: within twenty four hours
|
Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
|
within twenty four hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histology
Time Frame: within twenty four hours
|
To determine the histologic characteristics of the pancreatic tumor
|
within twenty four hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marine GILABERT, MD, Institut Paoli-Calmettes
Publications and helpful links
General Publications
- Fraunhoffer NA, Abuelafia AM, Chanez B, Bigonnet M, Gayet O, Roques J, Chuluyan E, Dusetti N, Iovanna J. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Commun (Lond). 2022 Nov;42(11):1212-1216. doi: 10.1002/cac2.12365. Epub 2022 Sep 30. No abstract available.
- Fraunhoffer NA, Abuelafia AM, Dusetti N, Iovanna J. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Cancer Commun (Lond). 2022 Oct;42(10):1028-1031. doi: 10.1002/cac2.12335. Epub 2022 Jul 18. No abstract available.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PACAomics / IPC 2011-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Tumor
-
Methodist Health SystemRecruitingSurgery | Liver Tumor | Pancreas TumorUnited States
-
McGill University Health Centre/Research Institute...Completed
-
National Cancer Institute (NCI)CompletedLocally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine TumorUnited States, Canada
-
Laser Tissue Welding, Inc.National Cancer Institute (NCI); CHI St. Luke's Health, TexasCompletedPancreatic Neoplasms | Pancreatic Adenocarcinoma | Pancreatic Cyst | Pancreatic Neuroendocrine Tumor | Pancreatic Polypeptide Tumor | Pancreatic Pseudocyst | Pancreatic Glucagonoma | Pancreas Injury | Pancreatic Cystadenoma | Pancreatic Tumor, Benign | Pancreas; Insulinoma | Pancreatic Teratoma | Pancreatic Vipoma and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Pancreatic Neuroendocrine Tumor | Pancreatic Neoplasm | Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Stage IV Pancreatic Neuroendocrine Tumor AJCC v8 | Unresectable Pancreatic Neuroendocrine TumorUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
Wei ZhouUnknownLiver Tumor | Gastric Tumor | Pancreatic TumorChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingPancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8United States
-
Chiba UniversityUnknownPancreatic Tumor | Bile Duct TumorJapan
-
University of Missouri-ColumbiaWithdrawnTumor of Exocrine PancreasUnited States
Clinical Trials on suspected pancreatic tumor
-
Assistance Publique - Hôpitaux de ParisRecruitingHepatocarcinoma | Pancreatic TumorFrance
-
Judith Dixon-HughesCancer Research UK; NHS Greater Glasgow and ClydeRecruitingNeoplasms PancreaticUnited Kingdom
-
AstraZenecaRecruiting
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
Karolinska University HospitalCompleted
-
University of ManitobaNatural Sciences and Engineering Research Council, Canada; ID Fusion Software... and other collaboratorsWithdrawn
-
University Hospital, AngersCompleted
-
Washington University School of MedicineNorthwestern University; University of OklahomaCompletedEndoscopic Retrograde Cholangiopancreatography (ERCP) | Bile Duct CannulationUnited States
-
Università Vita-Salute San RaffaeleCompletedLocally Advanced Pancreatic AdenocarcinomaItaly
-
Karolinska University HospitalUniversity Hospital, Linkoeping; Lund University Hospital; Sahlgren´s University... and other collaboratorsUnknownHealing Time of Post Operative Pancreatic FistulasSweden